Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

One of these mRNA pioneers has the products and pipeline to drive growth.

In 2026, Moderna (MRNA) and BioNTech (BNTX) are two mRNA companies that have transitioned beyond their initial focus on coronavirus vaccines. While both have faced challenges due to the vaccine's limited lifespan, they have ventured into oncology. Moderna's personalized cancer vaccine, intismeran, is in four phase 3 trials, while BioNTech's lead candidate, pumitamig, is a bispecific antibody progressing through seven global pivotal studies.

Despite BioNTech's substantial cash reserves and a promising pipeline, its future hinges on the leadership transition of its CEO and CMO, set to occur by February 1. Conversely, Moderna boasts several commercialized products, with its flu vaccine approved in 2022 and a broader rollout planned for the 2027-2028 respiratory season.

Its oncology-focused intismeran has shown promising results in a phase 3 melanoma trial and is being evaluated for other cancers. Moderna's stock has also surged, driven by investor confidence in its diversified portfolio. For these reasons, Moderna is recommended as the better investment between the two.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fool.com →

More in Finance & Markets

SK hynix Weighs Kioxia Bond Conversion

SK hynix is considering a plan to convert the convertible bonds it secured through its investment in the Japanese NAND flash manufacturer Kioxia into shares.According to the industry on Nov.

  • SK hynix considering converting Kioxia convertible bonds to shares.
  • Investment of 395 billion yen ($2.92 billion) in Kioxia via Bain Capital.
  • Bond conversion would grant SK hynix majority voting control in SPC2.

More from Friday 20 November →